Antibody News: Breaking Antibody News, Comments and Articles. - Page: 4

JCV Test Stratifies PML Risk in Antibody-Positive MS

A quantitative test for antibodies to JC virus stratifies antibody-positive patients with MS for the risk of contracting PML if they receive natalizumab, possibly allowing some with low antibody levels to continue the drug. Medscape Medical News

EHA 2013: Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma

Dr Henk Lokhorst will present the results from a phase I/II study in advanced Multiple Myeloma. Multiple myeloma is the second most common haematological cancer. It is a cancer of the plasma cells and it accounts for approx. 1% of all cancers. At...

Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013

ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it will host a Multiple Sclerosis-Estriol Investor Day on Tuesday, June 25, 2013 from 9:00 a.m. to 11:00 a.m. at the InterContinental New York Barclay Hotel in New York City. This event wi...

Inovio's Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals

BLUE BELL, Pa., June 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of its influenza DNA vaccine against the newly emergent, virulent H7N9 flu virus it achieved immune response levels exceeding what are considered protective levels in other common influenza subtypes. Interim results from a study in mice in a collaboration with rese...

A Beta-Secretase Inhibitor Hits the Skids in Alzheimer's

The brutal drumbeat of Alzheimer's clinical failure continues at Eli Lilly. After the Phase III failure of their gamma-secretase inhibitor semagacestat, and a delusional attempt to pretend that the anti-amyloid antibody solanezumab succeeded, now com...

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that novel antibody biomarkers could significantly improve diagnosis in rheumatoid arthritis.

[Seminar] Autoimmune hepatitis

Autoimmune hepatitis is a disease of the hepatic parenchyma that can present in acute or chronic forms. In common with many autoimmune diseases, autoimmune hepatitis is associated with non-organ-specific antibodies in the context of hepatic autoimmun...

Tocilizumab Effective In Juvenile Idiopathic Arthritis

A new study presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Art...

Novel biomarkers improve diagnosis in rheumatoid arthritis

(European League Against Rheumatism) Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that novel antibody biomarkers could significantly improve diagnosis in rheumatoid arthritis.

2013 BioProcess Theater Presentations Now Available on the BioProcess International Digital Media Website

Featuring the complete collection of podcasts as recorded in the BPI Theater during the 2013 BIO International Convention. Categories include Biosimilars, Single-Use Processing, Cell Therapy, Antibody/Nonantibody Manufacturing, and Vaccine Manufacturing. New York, NY (PRWEB) June 13, 2013 BioProcess International (BPI) announces the online publication of the complete set of BPI Theater podcasts p...

Eagle Biosciences Introduces Highly Sensitive Calprotectin ELISA Assay Kit

Eagle Biosciences expands their assay portfolio with the introduction of the highly sensitive and affordable Calprotectin ELISA Assay Kit. Nashua, NH (PRWEB) June 13, 2013 Eagle Biosciences is proud to announce the product launch of a brand new Calprotectin ELISA assay kit that offers the widest measurement range of any available assay (1-2000 µg/g stool). The Calprotectin ELISA assay kit is...

Celltrion presents Phase I data for CT-P13

Celltrion Inc. (KOSDAQ:068270) presented Phase I data comparing its CT-P13 with Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and partner Merck & Co. Inc. (NYSE:MRK) at the European League Against Rheumatism meeting on Thursday. In 250 patien...

KaloBios: An Undervalued Pharmaceutical Company With Remarkable Pipeline

ByBiomed Group:KaloBios Pharmaceuticals (KBIO) is a small-cap company focused on developing patient-targeted, first-in-class monoclonal antibodies using its proprietary Humaneered technology platform, with the intent to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Currently, the company's primary clinical focus is treating infectious and respiratory d...

Vaccine Manufacturing Innovators Awarded Fraunhofer Prize

Dr. Vidadi Yusibov, Executive Director of the Fraunhofer USA Center for Molecular Biotechnology (CMB), has received international recognition for development of the Center’s plant-based protein expression technology that lead to the construction of first in-its-kind good manufacturing practices (GMP) compliant automated bio-manufacturing plant. Developed...

Roche reject recycled for ophthalmic indication

An antibody that Roche licensed from Genmab for oncology indications, pursued into Phase II, then dropped two years ago, is restarting clinical development in an ophthalmic indication. According to Genmab, River Vision Development Corporation.....

Eisai Announces Sponsorship of CURE Benefit to Support Epilepsy Research and Awareness

WOODCLIFF LAKE, N.J., June 13, 2013 /PRNewswire/ -- Eisai Inc. announced today its platinum level sponsorship of the Citizens United for Research in Epilepsy (CURE) 15th Annual Chicago Benefit taking place Thursday, June 13, at Navy Pier, Chicago, IL. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) CURE is a nonprofit organization focused on finding a cure for epilepsy by r...

ADC Biotechnology extends North Wales facility with Technical Service Laboratory

ADC Biotechnology Ltd has extended its North Wales, UK facility with a new £125,000 Technical Service Laboratory. The new laboratory at St. Asaph is designed to meet growing demand for the company’s R&D services from developers of niche anti-c...

Intranasal Antibody Gene Transfer in Mice and Ferrets Protects Against Influenza Infection

Transmission of the influenza virus was blocked in animal models by a gene therapy technique that introduced a neutralizing antibody...

Researchers investigating the mystery of a tiny 'sin'

When a strain of bacteria invades a human body, the immune system responds by generating antibodies to neutralize the threat. However, during subsequent infections by a similar bacterium, the immune system has a tendency to fall back on its memory, g...

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) prog...

STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis

SPRING HOUSE, Pa., June 13, 2013 /PRNewswire/ -- Results from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 3 study published today in The Lancet showed patients with active psoriatic arthritis who received either STELARA® (ustekinumab) 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint compared with patients receiving place...

Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program

SEATTLE, June 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The first clinical trial with OMS721 will be conducted...

The AAPS Journal: Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics

Type: Brief CommunicationBiotherapeutic-reactive antibodies in treatment-naïve subjects (i.e., pre-existing antibodies) have been commonly detected during clinical immunogenicity assessments; however information on pre-existing antibody prevalence,...

PDL BioPharma Completes Regular Quarterly Dividend Payment

INCLINE VILLAGE, Nev., June 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 5, 2013, the record date. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) About PDL BioPharma PDL pioneered the humani...

Stelara Succeeds in Psoriatic Arthritis (CME/CE)

MADRID (MedPage Today) -- The monoclonal antibody ustekinumab (Stelara) had sustained benefits through a year of treatment among patients with active psoriatic arthritis, even if they had previously not done well on a tumor necrosis factor inhibitor,...